Q-omics provides the consensus-scored FCGR2C profile across patient tissues and cancer cell-line models. FCGR2C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCGR2C is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FCGR2C RNA expression shows 19,432 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where FCGR2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR2C survival associations across molecular data types. FCGR2C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR2C RNA expression–survival associations across cancer types. High FCGR2C expression shows unfavorable associations in KIRC, LGG, LUSC and GBM, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCGR2C RNA expression.
This table summarizes FCGR2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FCGR2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR2C shows lower tumor expression in UCEC and higher tumor expression in KIRC, THCA, KIRP, HNSC and LUAD. The KIRC box plot shows higher FCGR2C RNA expression in tumor versus normal tissue (log2 FC = +1.470, t-test p < 0.001).
This table shows molecular features associated with FCGR2C in patient tissues and cancer cell lines. In patient samples, FCGR2C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUSC.
